Ascendis Pharma A (ASND) Interest Expenses (2014 - 2026)

Ascendis Pharma A has disclosed Interest Expenses across 13 years of filings, most recently posting $78.7 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $78.7 million, up 267.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.3 million (up 36.35% YoY), and the FY2025 annual result was $240.6 million, up 125.09% from the prior year.
• Interest Expenses came in at $78.7 million for Q1 2026 at Ascendis Pharma A, up from -$72.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $83.8 million in Q1 2024 to a low of -$78.2 million in Q3 2025.
• The 5-year median for Interest Expenses is $10.2 million (2023), against an average of $10.0 million.
• Across the five-year window, Interest Expenses soared 22109.37% in 2023 and slumped 519338.58% in 2025, its largest moves.
• Ascendis Pharma A's Interest Expenses stood at -$314236.2 in 2022, then jumped by 22109.37% to $69.2 million in 2023, then tumbled by 100.02% to -$13891.7 in 2024, then plunged by 519338.58% to -$72.2 million in 2025, then surged by 209.12% to $78.7 million in 2026.
• The last three Interest Expenses figures came in at $78.7 million (Q1 2026), -$72.2 million (Q4 2025), and -$78.2 million (Q3 2025), per Business Quant data.